Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide high dose study in T2DM
NCT03495102Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2018
- Primary completion
- May 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
A Phase 3 trial of dulaglutide biosimilar 14028 injection in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Apr 2018; status: completed.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03495102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03495102.